BEGIN:VCALENDAR VERSION:2.0 PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4// BEGIN:VEVENT UID:20260611T064854EDT-7637W0fkk3@132.216.98.100 DTSTAMP:20260611T104854Z DESCRIPTION:McGill University and the Friends of CIHR are delighted to welc ome renowned scientist\, Dr. Lorne Tyrrell\, to deliver a keynote talk on 'Canadian Contributions to Pandemic Vaccines and Therapeutics”.\n\n \n\nRe gistration for this event is closed. Questions related to the lecture can be directed to meaghan.thurston [at] mcgill.ca (Meaghan Thurston. )\n\nOn Thursday September 8\, 2022\, at 4 p.m.\, Dr. Lorne Tyrrell\, the 2021 Hen ry G. Friesen International Prize Winner in Health Research\, will deliver a public lecture at the McGill Faculty Club. A visionary clinician-scient ist\, creative virologist\, entrepreneur\, and academic leader\, Dr. Tyrre ll will explore how Canadian scientists through both the Medical Research Council (MRC) of Canada and now the Canadian Institutes of Health Research (CIHR) have made many contributions to vaccine technology that helped ena ble the rapid response with new vaccines for SARSCoV2 – and discuss the im portance of discovery science.\n\nDr. David Lorne J. Tyrrell\, OC\, AOE\, MD\, PhD\, FRCP\, FRSC\, FCAHS\, is a Distinguished Professor at the Unive rsity of Alberta with major interests in the prevention and treatment of v iral diseases. He led the Faculty of Medicine and Dentistry from 1994 to 2 004 as Dean. In this capacity\, Health Sciences at U Alberta flourished wi th major capital developments\, including the Katz Group – Rexall Centre f or Pharmacy and Health Research and the Li Ka Shing Centre for Health Rese arch Innovation. During this period\, Dr. Tyrrell assumed national respons ibilities and chaired the Association of Canadian Medical Colleges\, throu gh which he facilitated the transition of the MRC to the CIHR. Dr. Tyrrell ’s most celebrated lifesaving accomplishment in collaboration with Morris Robbins was the licensing of the first oral anti-viral drug (Lamivudine) f or chronic hepatitus B HBV in 200 countries. This led to the establishment of the Li Ka Shing Institute of Virology in 2010 at the University of Alb erta\, where Dr. Tyrrell is its Founder and Director. He maintains active research programs in viral-host interactions\, development of a HCV vaccin e and an active program on SARS-CoV-2 vaccines\, diagnostics\, and antivir als.\n\nDr. Tyrrell has received numerous awards including the Prix Galien Canada Research Award (1998)\, Gold Medal of the Canadian Liver Foundatio n (2000)\, Alberta Order of Excellence (2000)\, Officer of the Order of Ca nada (2002)\, Frederic Newton Gisborne Starr Award of the Canadian Medical Association (2004)\, Fellow of the Royal Society of Canada (2004)\, Canad ian Medical Hall of Fame (2011)\, Killam Prize for Health Science (2015)\, and the FCIHR Award of Honour (2018). He is the recipient of the 2021 Hen ry G. Friesen International Prize in Health Research.\n\nThe Henry G. Frie sen International Prize in Health Research\, established in 2005 by the Fr iends of Canadian Institutes of Health Research (FCIHR)\, recognizes excep tional innovation by a visionary health leader of international stature.\n \nAn informal reception will follow the lecture.\n DTSTART:20220908T200000Z DTEND:20220908T213000Z LOCATION:Faculty Club\, CA\, QC\, Montreal\, H3A 0E5\, 3450 rue McTavish SUMMARY:Friesen Prize Public Lecture: 'Canadian Contributions to Pandemic V accines and Therapeutics' URL:https://www.mcgill.ca/research/channels/event/friesen-prize-public-lect ure-canadian-contributions-pandemic-vaccines-and-therapeutics-340443 END:VEVENT END:VCALENDAR